Aduro Biotech Joins Forces With Merck

Aduro Biotech Joins Forces With Merck

Aduro Biotech, a biopharmaceutical company with three distinct immunotherapy technologies, said it is partnering with Merck to try a new combination of therapies to fight gastric cancer. The companies will investigate the combination of Aduro’s experimental drug CRS-207 with Merck’s anti-PD-1 therapy Keytruda, or pembrolizumab, for the treatment of gastric cancer. The phase 1 study, planned to begin in H1, will enroll patients with metastatic gastric cancer who have failed […]

Read More ˃
CTI BioPharma Jumps 11.5%

CTI BioPharma Jumps 11.5%

CTI BioPharma is up 11.5% after the company said the PIX306 confirmatory trial of its commercial product PIXUVRI (pixantrone) continues to progress toward an announcement of top-line results later this year. If positive, the trial could provide the opportunity for full approval and label expansion by EMA, and discussions with the FDA about accelerated PIXUVRI approval in the US to treat patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. […]

Read More ˃